ScinoPharm Taiwan, Ltd. (TPE:1789)
18.95
+0.05 (0.26%)
Sep 30, 2025, 2:36 PM CST
ScinoPharm Taiwan Revenue
ScinoPharm Taiwan had revenue of 747.52M TWD in the quarter ending June 30, 2025, a decrease of -1.95%. This brings the company's revenue in the last twelve months to 3.19B, down -6.82% year-over-year. In the year 2024, ScinoPharm Taiwan had annual revenue of 3.41B with 6.91% growth.
Revenue (ttm)
3.19B
Revenue Growth
-6.82%
P/S Ratio
4.69
Revenue / Employee
5.92M
Employees
540
Market Cap
14.98B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.41B | 220.20M | 6.91% |
Dec 31, 2023 | 3.19B | -77.96M | -2.39% |
Dec 31, 2022 | 3.26B | 501.71M | 18.16% |
Dec 31, 2021 | 2.76B | -320.59M | -10.40% |
Dec 31, 2020 | 3.08B | 190.15M | 6.57% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Caliway Biopharmaceuticals | 44.83M |
PharmaEssentia | 12.63B |
Bora Pharmaceuticals Co., LTD. | 21.32B |
Lotus Pharmaceutical | 19.12B |
Lumosa Therapeutics | 37.25M |
Oneness Biotech | 112.57M |
Polaris Group | 64.02M |
Center Laboratories | 1.60B |